Jeffrey V. Poulton, EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 2,206 shares at $323.62 ($723K) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Open-market sale of $723k ALNY by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $323.62 | 65 | $21K | 2.9% |
| 2 | $324.65 | 124 | $40K | 5.6% |
| 3 | $325.63 | 356 | $116K | 16.0% |
| 4 | $326.81 | 541 | $177K | 24.5% |
| 5 | $327.67 | 454 | $149K | 20.6% |
| 6 | $328.71 | 138 |
| $45K |
| 6.3% |
| 7 | $329.71 | 234 | $77K | 10.7% |
| 8 | $330.85 | 112 | $37K | 5.1% |
| 9 | $331.93 | 129 | $43K | 5.9% |
| 10 | $332.64 | 53 | $18K | 2.4% |
| Total | $327.65 avg | 2,206 | $723K | 100% |
| Filing → |
| ALNY | SELL | 2026-01-14 | $1.0M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $3.4M | — | Filing → |
| ALNY | SELL | 2025-08-19 | $2.0M | — | Filing → |